Lido Advisors LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,085 shares of the medical research company’s stock, valued at approximately $1,205,000.
Several other institutional investors and hedge funds also recently made changes to their positions in CRL. New York Life Investment Management LLC boosted its stake in Charles River Laboratories International by 371.3% in the 3rd quarter. New York Life Investment Management LLC now owns 61,506 shares of the medical research company’s stock valued at $18,145,000 after purchasing an additional 48,455 shares during the period. AlphaCore Capital LLC grew its holdings in Charles River Laboratories International by 222.4% in the 3rd quarter. AlphaCore Capital LLC now owns 5,184 shares of the medical research company’s stock valued at $1,529,000 after buying an additional 3,576 shares in the last quarter. Retirement Systems of Alabama grew its holdings in Charles River Laboratories International by 1,246.1% in the 3rd quarter. Retirement Systems of Alabama now owns 136,211 shares of the medical research company’s stock valued at $40,184,000 after buying an additional 126,092 shares in the last quarter. Fulcrum Asset Management LLP bought a new position in Charles River Laboratories International during the 3rd quarter worth $85,000. Finally, Brighton Jones LLC increased its position in Charles River Laboratories International by 546.1% during the 3rd quarter. Brighton Jones LLC now owns 6,041 shares of the medical research company’s stock worth $1,782,000 after buying an additional 5,106 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.
Charles River Laboratories International Trading Down 0.8%
Shares of Charles River Laboratories International stock opened at $335.29 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76. Charles River Laboratories International, Inc. has a 12-month low of $146.20 and a 12-month high of $379.63. The company has a market capitalization of $16.07 billion, a price-to-earnings ratio of 368.45, a PEG ratio of 3.08 and a beta of 1.36. The firm’s 50-day moving average price is $312.13 and its two-hundred day moving average price is $228.83.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical research company reported $3.09 EPS for the quarter, beating the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company had revenue of $982.73 million during the quarter, compared to analysts’ expectations of $960.36 million. During the same period in the previous year, the company earned $2.43 EPS. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year. On average, analysts forecast that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Charles River Laboratories International news, Director James Foster sold 33,561 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. This represents a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 2,156 shares of the firm’s stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the sale, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 62,779 shares of company stock worth $20,127,838 over the last three months. 1.30% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $180.00 to $310.00 in a research report on Thursday, August 6th. Robert W. Baird upped their price target on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research note on Friday, September 25th. Evercore set a $330.00 price target on shares of Charles River Laboratories International in a research report on Friday, September 25th. Royal Bank Of Canada lifted their price objective on shares of Charles River Laboratories International from $322.00 to $352.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Monday, August 10th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $311.67.
View Our Latest Analysis on Charles River Laboratories International
Charles River Laboratories International Company Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
